Evaxion Biotech receives grant funding to design new polio vaccine

Evaxion receives funding support from the Gates Foundation to help the world eradicate polio by exploring design options for a new and unique vaccine. Despite polio vaccines being available for decades, the highly infectious viral disease is yet to be completely eradicated, meaning that the risk of a global polio resurgence and health crisis remain. The project will combine Evaxion’s clinically validated AI-Immunology platform with support from the Gates Foundation. Evaxion will deploy AI-Immunology to identify and combine various antigens to combat the virus. Based on these findings, a number of new antigen constructs will be designed for selection and validation. The work will be supported by the grant from the Gates Foundation, meaning there will be no financial cost for Evaxion.